Jean W Lee

Summary

Affiliation: MDS Pharma Services
Country: USA

Publications

  1. ncbi Fit-for-purpose method development and validation for successful biomarker measurement
    Jean W Lee
    Formerly MDS Pharma Services, Lincoln, Nebraska, USA
    Pharm Res 23:312-28. 2006
  2. ncbi Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers
    Jean W Lee
    Amgen Inc, Thousand Oaks, California 91320, USA
    Adv Cancer Res 96:269-98. 2007
  3. ncbi Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report
    Jean W Lee
    MDS Pharma Services, Lincoln, Nebraska, USA
    Pharm Res 22:499-511. 2005
  4. ncbi Supercritical fluid chromatography-tandem mass spectrometry for fast bioanalysis of R/S-warfarin in human plasma
    Roger A Coe
    MDS Pharma Services, 621 Rose Street, Lincoln, NE 68502, USA
    J Pharm Biomed Anal 42:573-80. 2006
  5. ncbi Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling
    Wayne A Colburn
    MDS Pharma Services, Phoenix, Arizona, USA
    Clin Pharmacokinet 42:997-1022. 2003
  6. ncbi Quantification of uric acid, xanthine and hypoxanthine in human serum by HPLC for pharmacodynamic studies
    Nancy Cooper
    MDS Pharma Services, Lincoln, NE 68501, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 837:1-10. 2006
  7. ncbi Quantification of recombinant human parathyroid hormone (rhPTH(1-84)) in human plasma by immunoassay: commercial kit evaluation and validation to support pharmacokinetic studies
    Richard L Sukovaty
    MDS Pharma Services, Lincoln, NE, USA
    J Pharm Biomed Anal 42:261-71. 2006
  8. ncbi A general approach for the quantitative analysis of bisphosphonates in human serum and urine by high-performance liquid chromatography/tandem mass spectrometry
    Lee S Zhu
    MDS Pharma Services, 621 Rose Street, Lincoln, NE 68502, USA
    Rapid Commun Mass Spectrom 20:3421-6. 2006

Collaborators

Detail Information

Publications8

  1. ncbi Fit-for-purpose method development and validation for successful biomarker measurement
    Jean W Lee
    Formerly MDS Pharma Services, Lincoln, Nebraska, USA
    Pharm Res 23:312-28. 2006
    ..Sample analysis within this context of fit-for-purpose method development and validation are well suited for successful biomarker implementation, allowing increased use of biomarkers in drug development...
  2. ncbi Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers
    Jean W Lee
    Amgen Inc, Thousand Oaks, California 91320, USA
    Adv Cancer Res 96:269-98. 2007
    ..Specific references to protein biomarkers for cancer drug development are also discussed...
  3. ncbi Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report
    Jean W Lee
    MDS Pharma Services, Lincoln, Nebraska, USA
    Pharm Res 22:499-511. 2005
    ....
  4. ncbi Supercritical fluid chromatography-tandem mass spectrometry for fast bioanalysis of R/S-warfarin in human plasma
    Roger A Coe
    MDS Pharma Services, 621 Rose Street, Lincoln, NE 68502, USA
    J Pharm Biomed Anal 42:573-80. 2006
    ..0% C.V. for S-warfarin; and the bias was 3.7 and 3.2% R.E., respectively. The method is sensitive, accurate, selective and robust, and was applied to a drug-interaction clinical study with rapid turnaround of sample analysis...
  5. ncbi Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling
    Wayne A Colburn
    MDS Pharma Services, Phoenix, Arizona, USA
    Clin Pharmacokinet 42:997-1022. 2003
    ....
  6. ncbi Quantification of uric acid, xanthine and hypoxanthine in human serum by HPLC for pharmacodynamic studies
    Nancy Cooper
    MDS Pharma Services, Lincoln, NE 68501, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 837:1-10. 2006
    ..The method was simple and robust with good accuracy and precision for the measurement of serum UA, X, and HX concentrations...
  7. ncbi Quantification of recombinant human parathyroid hormone (rhPTH(1-84)) in human plasma by immunoassay: commercial kit evaluation and validation to support pharmacokinetic studies
    Richard L Sukovaty
    MDS Pharma Services, Lincoln, NE, USA
    J Pharm Biomed Anal 42:261-71. 2006
    ....
  8. ncbi A general approach for the quantitative analysis of bisphosphonates in human serum and urine by high-performance liquid chromatography/tandem mass spectrometry
    Lee S Zhu
    MDS Pharma Services, 621 Rose Street, Lincoln, NE 68502, USA
    Rapid Commun Mass Spectrom 20:3421-6. 2006
    ..The general applicability of the approach was demonstrated by validation of bioanalytical methods for risedronate and alendronate in human serum and urine. Sensitivity was achieved at the pg/mL level with merely 100-200 microL of sample...